MAP2K1 and melanoma: However, a phase II clinical trial investigating MK-2206 plus selumetinib (MEK1/2 inhibitor) in stage III/IV melanoma patients who previously failed vemurafenib or dabrafenib treatment was terminated due to slow accrual (NCT01519427).